What Pharmacists’ Advice Reveals About Drug Affordability
A recent Fast Company article shares practical advice from pharmacists on how patients can lower their out-of-pocket prescription costs, from coupons and discount cards to cash-pay options and direct-to-consumer platforms. The guidance is helpful. It is also revealing.
Medicare Drug Spending Is Rising. That’s Not the Problem.
Medicare is spending a lot more on prescription drugs. In 2024 alone, the U.S. government covered a record $16 billion to Part D plans. But is that a bad thing? In Forbes, contributor Joshua P. Cohen argues the surge is evidence that one of the most consequential Medicare reforms in decades is doing exactly what it was designed to do.
Medicare Costs Depend on Prescription Strategy in 2026
Medicare beneficiaries are concerned. The new year is bringing higher premiums, higher deductibles, and growing uncertainty about their medical coverage. Medicare open enrollment for 2026 closed on December 7 so for most beneficiaries, coverage decisions are locked in.
What isn’t locked in is what they’ll pay.
The FDA Just Raised the Bar on Biosimilar Advertising. Here’s Why It Matters for Pharmacy Spend
Biosimilars have suffered the same credibility gap generics once faced, a problem science alone could not solve. Despite years of FDA approvals, clinical validation, and documented savings, adoption has lagged. The barrier has never been evidence. It has been how, when, and by whom that evidence is communicated.
Generics and Biosimilars: The Most Reliable Savings Lever in Employer Pharmacy
Generics and biosimilars rarely dominate broker conversations, yet they drive some of the most dependable pharmacy savings available to employers. While much of the market remains fixated on pipeline risk and brand pricing volatility, these alternatives quietly reduce spend year after year without compromising clinical integrity. For brokers advising cost-constrained employers, this matters. Pharmacy remains […]
Flat Enrollment Won’t Save Medicaid Budgets
The new KFF survey of state Medicaid directors confirms what many in the field suspected: even after the unwinding, even with enrollment stabilizing, Medicaid costs are climbing at a pace that outstrips everything else. States expect enrollment to stay flat in FY 2026. Yet they also predict nearly 8 percent growth in spending.
RazorMetrics Named Winner of 2025 FAVE Awards’ Innovative Company Category
AUSTIN, Texas – Nov. 14, 2025 – RazorMetrics, a leading innovator in pharmacy cost containment technology, has been named the winner for the 2025 FAVE Awards in the FAVE Innovative Company category. Hosted by the Austin Young Chamber, the FAVE Awards celebrate local businesses and professionals driving innovation, creativity, and impact across Central Texas. The […]
Will the Medicare $2,000 Cap Tame Drug Prices?
Prescription drug costs are rising faster than inflation, and for Medicare beneficiaries, that is more than a budget concern. When specialty and biologic drugs run upwards of tens of thousands of dollars a year, patients are forced to choose between medication and basic household needs. The Medicare Part D redesign launched in 2025 under the Inflation Reduction Act aims to change that. The question is: how much relief it will really bring?
The Power Behind the Platform: Why P&T Committees Matter More Than Ever
Clinical credibility isn’t just a box to check. It’s the difference between a recommendation that physicians trust and one they ignore. In a healthcare system defined by constant change, the Pharmacy & Therapeutics (P&T) Committee is what keeps every decision clinically sound, policy-aligned, and adaptable. At RazorMetrics, our P&T Committee sits at the center of […]